Serum Fibrosis Marker Levels Decrease After Successful Antiviral Treatment in Chronic Hepatitis C Patients With Advanced Fibrosis

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 2, 2009, Pages 219-226

  Fontana, Robert J ^a   Bonkovsky, Herbert L ^b   Naishadham, Deepa ^c   Dienstag, Jules L ^d,e   Sterling, Richard K ^f   Lok, Anna S F ^a   Su, Grace L ^a,g  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^g Ann Arbor Veterans Administration Health System 11R   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; HYALURONIC ACID; PEGINTERFERON ALPHA2A; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RIBAVIRIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 58849097713     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.10.034     Document Type: Article

References (21)

1. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferona2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
2. Shifffman M.L., DiBisceglie A.M., Lindsay K.L., et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology 126 (2004) 1015-1023
3. Shiffman M.L., Hoffman C.M., Contos M.J., et al. A randomized controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117 (1999) 1164-1171
4. Fontana R.J., Goodman Z.D., Dienstag J.L., et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 47 (2008) 789-798
5. Rosenberg W.M.C., Voelker M., Thiel R., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127 (2004) 1704-1713
6. Kamal S.M., Turner B., He Q., et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 43 (2006) 771-779
7. Mehta P., Ploutz-Snyder R., Nandi J., et al. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 103 (2008) 1-9
8. Lichtinghagen R., Bahr M.J., Wehmeier M., et al. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci 105 (2003) 373-382
9. Saitou Y., Shiraki K., Yamanaka Y., et al. Non-invasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated disease. World J Gastroenterol 11 (2005) 476-481
10. Poynard T., McHutchison J., Manns M., et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 38 (2003) 481-492
11. Lee W.M., Dienstag J.L., Lindsay K.L., et al. Evolution of the HALT-C trial: pegylated interferon as a maintenance therapy for chronic hepatitis C in previous Interferon nonresponders. Control Clin Trials 25 (2004) 472-492
12. Mitsuda A., Suou T., Ikuta Y., et al. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C. J Hepatol 32 (2000) 666-672
13. Patel K., Lajoie A., Heaton S., et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 18 (2003) 253-257
14. Berg S. Hyaluronan turnover in relation to infection and sepsis. J Intern Med 242 (1997) 73-77
15. Han C.Y., Subramanian S., Chan C.K., et al. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes 56 (2007) 2260-2273
16. Solis-Herruzo J.A., Castellano G., Fernandez I., et al. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic Hepatitis C. J Hepatol 33 (2000) 812-817
17. Framarin L., Avataneo T., Salzedo E., et al. Vertebral osteopenia due to bone marrow hyperplasia during interferon-a and ribavirin therapy for chronic hepatitis C. Dig Liver Dis 35 (2003) 732-734
18. Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement and loss of detectable HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med 127 (1997) 875-881
19. Guido M., Rugge M., Chemello L., et al. Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J Hepatol 24 (1996) 301-307
20. Persico M., Persico E., Suozzo R., et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 118 (2000) 760-764
21. Cales P., Obert F., Michalak S., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42 (2005) 1373-1381